{"version":"1.0","type":"rich","width":"560px","height":"140px","title":"\u00a0The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma","url":"https:\/\/www.myelomasociety.org\/the-ifm2017-03-phase-3-trial-a-dexamethasone-sparing-regimen-with-daratumumab-and-lenalidomide-for-frail-patients-with-newly-diagnosed-multiple-myeloma\/","author_name":"IMSound","author_url":"https:\/\/www.myelomasociety.org","thumbnail_url":"https:\/\/www.myelomasociety.org\/wp-content\/uploads\/2024\/07\/IMSound-Logo-only-v2.png","html":"<iframe width=\"560px\" height=\"140px\" src=\"https:\/\/www.myelomasociety.org\/the-ifm2017-03-phase-3-trial-a-dexamethasone-sparing-regimen-with-daratumumab-and-lenalidomide-for-frail-patients-with-newly-diagnosed-multiple-myeloma\/?standalonePlayer\"><\/iframe>"}